Genes affect medication side effects
- Trial ID
- NCT06329739
- Official Title
- Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes in Patients Undergoing Dopaminergic Treatment
- Goal
- Genes affect medication side effects
- Status
- RECRUITING
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Study Type
- OBSERVATIONAL
- Enrollment
- 68 participants
- Conditions
- Parkinson Disease
- Interventions
- Clinical examinations and clinical scales administration
Plain-Language Summary
The goal is to find out whether inherited genetic differences influence thinking, mood, and behavior in people with Parkinson's who are taking dopaminergic medications. Participants who have had genetic testing for Mendelian forms of Parkinson's get detailed clinical exams and standardized cognitive and behavioral scales, and researchers compare those outcomes by genetic status; levodopa and dopamine agonists boost brain dopamine to improve movement but can also cause hallucinations, sleep and memory changes, and impulse control problems, so the study looks at whether genetics affects those effects. Adults 18 and older with a Parkinson's diagnosis who are on levodopa and/or dopamine agonists and have undergone genetic testing are eligible, deep brain stimulation recipients are excluded, and participants must be able to give informed consent.
Locations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Clinical examinations and clinical scales administration. The goal is to find out whether inherited genetic differences influence thinking, mood, and behavior in people with Parkinson's who are taking dopaminergic medications. Participants who have had genetic testing for Mendelian forms of Parkinson's get detailed clinical exams and standardized cognitive and behavioral scales, and researchers compare those outcomes by genetic status; levodopa and dopamine agonists boost brain dopamine to improve movement but can also cause hallucinations, sleep and memory changes, and impulse control problems, so the study looks at whether genetics affects those effects. Adults 18 and older with a Parkinson's diagnosis who are on levodopa and/or dopamine agonists and have undergone genetic testing are eligible, deep brain stimulation recipients are excluded, and participants must be able to give informed consent.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 10 years.